Date updated:02-24-2007
From Stockerblog.
Stem Cell Stocks: The Growth Industry of the Future?
On February 16, the state of California distributed $45 million in research grants to approximately 20 state universities and nonprofit laboratories for stem cell research. Four other states, Connecticut, Illinois, Maryland, and New Jersey, are also funding stem cell research. California is contributing almost twice as much as the Federal government towards research. Arnold Schwarzenegger, Governor of California, said "Today, we are making history."
There are only a limited number of stocks which are pure plays or semi-pure plays in the stem cell industry. However, if governmental funding increases, if private research continues, and if there are any major breakthroughs, then this could be a very huge industry. Check out the following list of public companies that could benefit greatly from all of this.

-
STEM
Stemcells - $1.13
- -0.88%
- $1.13
StemCells Inc. (STEM) This Palo Alto company is involved in the discovery and development of adult stem cell therapeutics for treating damage to the central nervous system, liver, and pancreas. Negative earnings, P/S is a high 1771.

-
LIFC
Lifecell Corporat - $0.00
- 0.00%
- $N/A
LifeCell Corporation (LIFC) This New Jersey company develops and sells human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgery. They produce a three-dimensional structured regenerative human tissue matrix. P/E 45, P/S 6.3.

-
MEDI
Medi - $0.00
- N/A
- $N/A
MedImmune (MEDI) This Maryland company develops, manufactures, and markets products for the treatment of infectious diseases, inflammatory diseases, and cancer. P/E 167, P/S 6.2.

-
AVII
Avi Biopharma - $1.44
- -3.36%
- $1.46
AVI Biopharma (AVII) The Oregon based company is involved in the development of therapeutic products based on NEUGENE antisense technology to treat various diseases. Negative earnings, P/S is 100.

-
CRA
Celera Corporatio - $6.35
- 0.00%
- $6.31
Celera Group (CRA) This NYSE company, founded in 1937, is involved in the discovery and validation of new diagnostic markers, using proprietary genomics and proteomics discovery platforms and diagnostic products based on those markers. They collaborate with Abbott Laboratories, Genentech, General Electric and Merck. Negative earnings, P/S is 24.

-
CELG
Celgene Corporati - $53.05
- +2.35%
- $51.57
Cellgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. Their primary product includes THALOMID, for the treatment of erythema nodosum leprosum. Last year, the company received patent on placental stem cell recovery. P/E is 316, P/S is 21.

-
CRIS
Curis - $2.15
- -0.92%
- $2.13
Curis, Inc. (CRIS) This Massachusetts based company is involved in the discovery, development, and marketing of products that modulate key regulatory signaling pathways which control the repair and regeneration of human tissues and organs. It collaborates with Genentech, Procter & Gamble, and Wyeth. Negative earnings, P/S is 4.9.

-
DNDN
Dendreon Corporat - $28.61
- +2.99%
- $28.18
Dendreon Corporation (DNDN) This company is involved in the discovery, development, and marketing of active immunotherapies, monoclonal antibodies, and small molecule product candidates to treat cancer. They manufacture the DACSÒSC stem cell enrichment device. Negative earnings, very high P/S of 1500.
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. WisdomTree Intl Consum...
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » John Shier
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...
By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...
By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...
By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...
A. The only one I own : SLX,
too hard pick a winner out all of them
Analyst Downgrades for Nov. 2, 2009. Read more here. more
Here are some of the largest % gainers from Nov. 2, 2009. more
Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more













Comments not available